The cancer ratio plus in the differential diagnosis of pleural effusions
Biochemia medica · 2026
DOI: 10.11613/bm.2026.010502 ↗Kurz gefasst
Scoping Review in der Zeitschrift Biochemia medica, 2026. Verfasst von Yasmine Bendimrad und 3 weiteren Autor:innen. Beteiligte Einrichtung: Mohammed VI Faculty of Pharmacy, Mohammed VI University of Sciences and Health, Casablanca, Morocco. Hauptthemen laut MEDLINE: Pleural Effusion, Malignant, Pleural Effusion, Tuberculosis, Pleural. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Introduction
Differentiating between malignant pleural effusion (MPE) and tuberculous pleural effusion (TPE) remains challenging in clinical practice. The cancer ratio plus (CR+), a potential diagnostic tool calculated as serum lactate dehydrogenase/(pleural adenosine deaminase x pleural lymphocyte percentage) has emerged to address this diagnostic challenge. This scoping review maps the available evidence on its diagnostic performance. Materials and methods: We conducted a systematic search of PubMed, Scopus, and Web of Science databases from inception to April 2025. Eligible studies assessed the accuracy of CR+ in distinguishing MPE from TPE. Data on study design, cut-off values, sensitivity, specificity, area under the curve (AUC), and likelihood ratios were extracted and synthesized narratively.
Results
Six studies comprising 881 patients were included. Reported cut-off values varied widely (5.7 - 41.0), as did sensitivity (74.3 - 97.6%) and specificity (36.6 - 94.1%). Most studies, however, reported good discriminatory power with AUC values generally above 0.80. The highest diagnostic accuracy was observed in one study, which reported a sensitivity of 97.6%, a specificity of 94.1%, and an AUC of 0.86. Differences in cut-off thresholds, study populations, local tuberculosis epidemiology, and laboratory methodology (particularly lymphocyte quantification) likely contributed to this heterogeneity.
Conclusions
The CR+ appears promising as a non-invasive tool using routine parameters for differentiating MPE from TPE, but diagnostic performance varies across settings. The heterogeneity in optimal cut-off values highlights the need for local validation before clinical adoption. Future research should standardize methodology and assess its impact on decision-making and patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Mohammed VI Faculty of Pharmacy, Mohammed VI University of Sciences and Health, Casablanca, Morocco.
- Laboratory Medicine, Cheikh Khalifa International University Hospital, Mohammed VI University of Sciences and Health, Casablanca, Morocco.
- Mohammed VI Faculty of Medicine, Mohammed VI University of Sciences and Health, Casablanca, Morocco.
- Immunopathology-Immunotherapy-Immunomonitoring Laboratory, Mohammed VI University of Sciences and Health, Casablanca, Morocco.
Zitieren
APA
Bendimrad, Y., Mellah, L., Snoussi, M., & El Bakkouri, J. (2026). The cancer ratio plus in the differential diagnosis of pleural effusions. Biochemia medica. https://doi.org/10.11613/bm.2026.010502
Vancouver
Bendimrad Y, Mellah L, Snoussi M, El Bakkouri J. The cancer ratio plus in the differential diagnosis of pleural effusions. Biochemia medica. 2026. doi:10.11613/bm.2026.010502
BibTeX
@article{Bendimrad2026,
author = {Bendimrad, Yasmine and Mellah, Lamia and Snoussi, Malak and El Bakkouri, Jalila},
title = {The cancer ratio plus in the differential diagnosis of pleural effusions},
journal = {Biochemia medica},
year = {2026},
doi = {10.11613/bm.2026.010502}
}
EUVIMED